title: Downregulation of T cell receptor expression by CD8(+) lymphocytes in kidney allografts.
abstract: Allospecific CD8(+) T lymphocytes are an important component of the cellular response in allograft rejection. These cells recognize and engage MHC class I antigens, leading to allospecific cytolytic responses and graft rejection. In mouse kidney allografts that survive to 3 wk after transplantation, we noted that the majority of CD8(+) cells do not express surface alpha/beta T cell receptor alpha/beta(TCR), gamma/deltaTCR, or CD3. However, these CD8(+)TCR- cells did express surface markers characteristic of T cells, including Thy1.2, CD2, and CD5. In addition, the CD8(+)TCR- cells expressed mRNA for TCR Vbeta gene families, and nearly half stained positive for cytoplasmic Vbeta8 protein, suggesting that they are T cells that have downregulated alpha/betaTCR protein expression from their cell surfaces. When these surface TCR- cells were isolated from kidney allografts by flow cytometry and cultured in the presence of either allogeneic or syngeneic stimulators, nearly 100% of cells reacquired normal levels of alpha/betaTCR expression with disproportionate usage of Vbeta8 chains. After recovery of their surface TCR expression, the CD8(+)TCR- population demonstrated strong alloreactivity in culture. These results suggest that the substantial number of CD8(+)TCR- cells found in long-term surviving mouse kidney allografts are alpha/beta-T cells that have downregulated their cell surface expression of TCR. While in other systems this phenotype may identify cells that have engaged antigen, our results indicate that loss of TCR expression by CD8(+) kidney graft-infiltrating cells may not depend on antigen engagement and that elements in the microenvironment of the kidney graft play a key role in this process. Factors that modulate expression of TCR by graft-infiltrating lymphocytes may have an important role in regulating rejection responses.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, and Veterans Administration Medical Center, Durham, North Carolina 27710, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Mannon
authors.forename: B L
authors.initials: BL
authors.lastname: Kotzin
authors.forename: C
authors.initials: C
authors.lastname: Nataraj
authors.forename: K
authors.initials: K
authors.lastname: Ferri
authors.forename: E
authors.initials: E
authors.lastname: Roper
authors.forename: R J
authors.initials: RJ
authors.lastname: Kurlander
authors.forename: T M
authors.initials: TM
authors.lastname: Coffman
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry*; D016207:Cytokines / Q000235:genetics; D015536:Down-Regulation; D006084:Graft Rejection; D016030:Kidney Transplantation / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D012333:RNA, Messenger / Q000032:analysis; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis*; D014184:Transplantation, Homologous
chemical_list: D016207:Cytokines; D012333:RNA, Messenger; D016693:Receptors, Antigen, T-Cell, alpha-beta